Literature DB >> 25402706

Changes in HIV reservoirs during long-term antiretroviral therapy.

Feiyu F Hong1, John W Mellors.   

Abstract

PURPOSE OF REVIEW: To review current knowledge about the impact of long-term combination antiretroviral therapy (cART) on HIV reservoirs. RECENT
FINDINGS: The number of HIV-infected cells that persist during long-term antiretroviral therapy is associated with the stage of HIV infection at the time of treatment initiation. Initiation of cART reduces the number of infected cells over the first 4 years of therapy, but thereafter there is no further decline despite long-term effective cART. The remarkable stability of infected cell numbers is likely due to a balance among homeostatic or antigen-driven proliferation of infected memory T-cells subsets, clonal expansion of a subset of infected cells as a consequence of specific retroviral integration sites, and death of other infected cells. At present, there is no effective means of accelerating the decay of infected cells in individuals initiated on cART during chronic HIV infection.
SUMMARY: Given the stability and difficulty in eliminating HIV-infected cells, early initiation of cART in treatment-naïve HIV-infected patients is currently the most effective way to limit the size and diversity of HIV reservoirs.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25402706      PMCID: PMC4567251          DOI: 10.1097/COH.0000000000000119

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  60 in total

1.  Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.

Authors:  F García; M Plana; C Vidal; A Cruceta; W A O'Brien; G Pantaleo; T Pumarola; T Gallart; J M Miró; J M Gatell
Journal:  AIDS       Date:  1999-07-30       Impact factor: 4.177

2.  Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals.

Authors:  Michael A Poles; W John Boscardin; Julie Elliott; Philip Taing; Marie M P Fuerst; Ian McGowan; Stephen Brown; Peter A Anton
Journal:  J Acquir Immune Defic Syndr       Date:  2006-09       Impact factor: 3.731

3.  Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro.

Authors:  Kersten K Koelsch; Lin Liu; Richard Haubrich; Susanne May; Diane Havlir; Huldrych F Günthard; Caroline C Ignacio; Paula Campos-Soto; Susan J Little; Robert Shafer; Gregory K Robbins; Richard T D'Aquila; Yuji Kawano; Karen Young; Phillip Dao; Celsa A Spina; Douglas D Richman; Joseph K Wong
Journal:  J Infect Dis       Date:  2008-02-01       Impact factor: 5.226

4.  In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA.

Authors:  Mark Sharkey; Karine Triques; Daniel R Kuritzkes; Mario Stevenson
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells.

Authors:  Justin R Bailey; Ahmad R Sedaghat; Tara Kieffer; Timothy Brennan; Patricia K Lee; Megan Wind-Rotolo; Christine M Haggerty; Ashrit R Kamireddi; Yi Liu; Jessica Lee; Deborah Persaud; Joel E Gallant; Joseph Cofrancesco; Thomas C Quinn; Claus O Wilke; Stuart C Ray; Janet D Siliciano; Richard E Nettles; Robert F Siliciano
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

6.  Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1.

Authors:  Matthew C Strain; Susan J Little; Eric S Daar; Diane V Havlir; Huldrych F Gunthard; Ruby Y Lam; Otto A Daly; Juin Nguyen; Caroline C Ignacio; Celsa A Spina; Douglas D Richman; Joseph K Wong
Journal:  J Infect Dis       Date:  2005-03-29       Impact factor: 5.226

7.  Contribution of cellular HIV-1 DNA quantification to the efficacy analysis of antiretroviral therapy: a randomized comparison of 2 regimens, including 3 drugs from 2 or 3 classes (TRIANON, ANRS 081).

Authors:  Laurence Morand-Joubert; Fabienne Marcellin; Odile Launay; Sonia Guiramand-Hugon; Laurence Gérard; Patrick Yeni; Jean-Pierre Aboulker
Journal:  J Acquir Immune Defic Syndr       Date:  2005-03-01       Impact factor: 3.731

8.  Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.

Authors:  Sarah Palmer; Frank Maldarelli; Ann Wiegand; Barry Bernstein; George J Hanna; Scott C Brun; Dale J Kempf; John W Mellors; John M Coffin; Martin S King
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-10       Impact factor: 11.205

9.  ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia.

Authors:  Frank Maldarelli; Sarah Palmer; Martin S King; Ann Wiegand; Michael A Polis; JoAnn Mican; Joseph A Kovacs; Richard T Davey; Diane Rock-Kress; Robin Dewar; Shuying Liu; Julia A Metcalf; Catherine Rehm; Scott C Brun; George J Hanna; Dale J Kempf; John M Coffin; John W Mellors
Journal:  PLoS Pathog       Date:  2007-04       Impact factor: 6.823

10.  Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART.

Authors:  Ahmad R Sedaghat; Robert F Siliciano; Claus O Wilke
Journal:  BMC Infect Dis       Date:  2008-01-02       Impact factor: 3.090

View more
  17 in total

1.  An Exception to the Rule or a Rule for the Exception? The Potential of Using HIV-Positive Donors in Canada.

Authors:  Alissa J Wright; Caren Rose; Maeghan Toews; Michel Paquet; Daniel Corsilli; Jean-François Le Cailhier; John S Gill
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

2.  HIV persists throughout deep tissues with repopulation from multiple anatomical sources.

Authors:  Antoine Chaillon; Sara Gianella; Simon Dellicour; Stephen A Rawlings; Timothy E Schlub; Michelli Faria De Oliveira; Caroline Ignacio; Magali Porrachia; Bram Vrancken; Davey M Smith
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

3.  Effects of Framingham 10-Year Cardiovascular Risk Score and Viral Load on Brain Integrity in Persons With HIV.

Authors:  Michelle Glans; Sarah A Cooley; Florin Vaida; Anna Boerwinkle; Dimitre Tomov; Kalen J Petersen; Alexander Rosenow; Robert H Paul; Beau M Ances
Journal:  J Acquir Immune Defic Syndr       Date:  2022-05-01       Impact factor: 3.771

Review 4.  Eradication of HIV-1 from the macrophage reservoir: an uncertain goal?

Authors:  Wasim Abbas; Muhammad Tariq; Mazhar Iqbal; Amit Kumar; Georges Herbein
Journal:  Viruses       Date:  2015-03-31       Impact factor: 5.048

5.  Impact of a decade of successful antiretroviral therapy initiated at HIV-1 seroconversion on blood and rectal reservoirs.

Authors:  Eva Malatinkova; Ward De Spiegelaere; Pawel Bonczkowski; Maja Kiselinova; Karen Vervisch; Wim Trypsteen; Margaret Johnson; Chris Verhofstede; Danny de Looze; Charles Murray; Sabine Kinloch-de Loes; Linos Vandekerckhove
Journal:  Elife       Date:  2015-10-06       Impact factor: 8.140

Review 6.  Targeting the Brain Reservoirs: Toward an HIV Cure.

Authors:  Céline Marban; Faezeh Forouzanfar; Amina Ait-Ammar; Faiza Fahmi; Hala El Mekdad; Fadoua Daouad; Olivier Rohr; Christian Schwartz
Journal:  Front Immunol       Date:  2016-09-30       Impact factor: 7.561

7.  HIV persists in CCR6+CD4+ T cells from colon and blood during antiretroviral therapy.

Authors:  Annie Gosselin; Tomas Raul Wiche Salinas; Delphine Planas; Vanessa S Wacleche; Yuwei Zhang; Rémi Fromentin; Nicolas Chomont; Éric A Cohen; Barbara Shacklett; Vikram Mehraj; Maged P Ghali; Jean-Pierre Routy; Petronela Ancuta
Journal:  AIDS       Date:  2017-01-02       Impact factor: 4.177

8.  Factors Associated With Persistence of Plasma HIV-1 RNA During Long-term Continuously Suppressive Firstline Antiretroviral Therapy.

Authors:  Alessandra Ruggiero; Alessandro Cozzi-Lepri; Apostolos Beloukas; Douglas Richman; Saye Khoo; Andrew Phillips; Anna Maria Geretti
Journal:  Open Forum Infect Dis       Date:  2018-02-03       Impact factor: 3.835

Review 9.  Immune Activation, Inflammation, and Non-AIDS Co-Morbidities in HIV-Infected Patients under Long-Term ART.

Authors:  Sonia Zicari; Libera Sessa; Nicola Cotugno; Alessandra Ruggiero; Elena Morrocchi; Carlo Concato; Salvatore Rocca; Paola Zangari; Emma C Manno; Paolo Palma
Journal:  Viruses       Date:  2019-02-27       Impact factor: 5.048

10.  Elite Control, Gut CD4 T Cell Sparing, and Enhanced Mucosal T Cell Responses in Macaca nemestrina Infected by a Simian Immunodeficiency Virus Lacking a gp41 Trafficking Motif.

Authors:  Matthew W Breed; Samra E Elser; Workineh Torben; Andrea P O Jordan; Pyone P Aye; Cecily Midkiff; Faith Schiro; Chie Sugimoto; Xavier Alvarez-Hernandez; Robert V Blair; Anoma Somasunderam; Netanya S Utay; Marcelo J Kuroda; Bapi Pahar; Roger W Wiseman; David H O'Connor; Celia C LaBranche; David C Montefiori; Mark Marsh; Yuan Li; Michael Piatak; Jeffrey D Lifson; Brandon F Keele; Patricia N Fultz; Andrew A Lackner; James A Hoxie
Journal:  J Virol       Date:  2015-07-29       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.